A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 600 participants.
Also called NCT06972472
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 600 participants
- Sponsor
- Registry
-
NCT06972472 -
2025-521098-14-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, China, Czechia, Germany, Japan, Puerto Rico
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06972472. Randomized; double masking; primary purpose treatment. Start 2025-05-19 (actual); primary completion 2027-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06972472- Content hash
ed0c0fbde370657478a750812d36a5951919960fae2b5106f3a73d9bc1eba8b7